Eli Lilly and (LLY) Ownership

LLY$1,437.76+5.46 +0.38%
Drug Manufacturers - GeneralMega CapGrowth StockHigh Quality
Compare
Market cap$1.35TEnterprise value$1.38TRevenue (TTM)$86.46BMarket positionTop 1%

Score

56
Neutral
Value
17
Quality
82
Growth
68

Ownership data loads after the page opens.

Eli Lilly and (LLY) Ownership

LLY price $1,437.76 +5.46 +0.38%

Ticker
LLY
Price
$1,437.76
Change
+5.46 +0.38%
Market cap
$1.35T
P/E
46.50
Forward P/E
30.59
Dividend yield
0.47%
Beta
0.45
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
56
Value
17
Quality
82
Growth
68

Stocklytics score rationale: value 17, quality 82, growth 68.

AI Score 62. The score reflects strong reported profitability, with a net margin of 0.319, offset by elevated valuation multiples of 45.8899 P/E and 31.3949 price-to-book. Growth, estimates, and price-trend evidence were not provided, limiting confidence

Summary

Eli Lilly and Company operates in Healthcare within Drug Manufacturers - General. The company reports a net margin of 31.9% and a dividend yield of 0.5%.

Valuation

The stock trades at a P/E of 45.9 and a price-to-book ratio of 31.4. These multiples indicate a valuation that depends on sustained earnings strength.

Quality

A net margin of 31.9% indicates strong profitability based on the available facts. No balance-sheet, cash-flow, or return-on-capital figures are provided.

Growth

No revenue, earnings-growth, estimate-revision, or price-trend data are provided. Growth cannot be assessed from the supplied facts.

Risks

The P/E of 45.9 and price-to-book ratio of 31.4 create valuation risk if profitability or growth expectations weaken. The dividend yield of 0.5% provides limited income support.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener